Posts Tagged ‘merck chemicals’
Merck Comes Up With Great Profits
Results for the third quarter of performance and acquisitions are out. The results look promising for the entire sector. Well in conformity with the trend has been the performance of Merck and Co.. Lower charges and high sales have provided the basis for the sky rocketing of the net incomes of the company. Diabetes and cervical cancer drugs (Januvia and Gardasil respectively) have shown appreciable increase in slaes.
Net income has been recorded at $169 billion. The figure for the same period last year was only $342 million. The reason for the poor performance last year included a charge of $950 million against the legal settlements for the withdrawn drug rofecoxib (a drug for arthritis sold earlier in the name of Vioox).
Overall sales in this quarter crossed $12 billion. It is 8 percent higher but includes 5 percent of it through foreign exchange. The best-selling drug from Merck continues to be Singulair (composition: montelukast). This anti-asthma drug has shown a rise of 10 percent over the last year’s sale during the third quarter. It contributed $1.34 billion in the sales.
The other prominent contributor products to the profit were: Januvia (sitagliptin), Janumet (sitagliptin+ metformin)—both the drugs have shown a rise of over 40 percent. Next in the line are Isentress (raltegravir) and vaccine against cervical cancer Gardasil.
The company has lost on the front of its new drug against Hepatitis C, Victrelis (boceprevir). It owes its fall in sale to the US.